ALB and myeloid sarcoma: Furthermore, CSF adiponectin levels are positively correlated with systemic serum levels, with the CSF/serum adiponectin ratio correlated with the CSF/serum albumin ratio, indicating that CSF adiponectin might represent an additional marker of blood–brain barrier damage in MS patients [20, 33].